{"id":496,"date":"2017-05-02T14:04:55","date_gmt":"2017-05-02T18:04:55","guid":{"rendered":"https:\/\/geiselmed2.dartmouth.edu\/dartlab\/clinical-trial-studies\/"},"modified":"2020-08-08T05:13:30","modified_gmt":"2020-08-08T09:13:30","slug":"clinical-trial-studies","status":"publish","type":"page","link":"https:\/\/geiselmed.dartmouth.edu\/dartlab\/services\/clinical-trial-studies\/","title":{"rendered":"Clinical Trial Studies"},"content":{"rendered":"

DartLab offers a range of services to facilitate Phase I and II clinical trials, including panel development, cell staining, cell sorting, flow cytometry, and data analysis. To arrange services for a clinical trial, please <\/span>contact Dr. Smith<\/a><\/span> to consult on research needs and experimental design. <\/span><\/p>\n

 <\/p>\n

Previous Clinical Trials<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Title<\/strong><\/td>\nPhase<\/strong><\/td>\nPI<\/strong><\/td>\nCategory<\/strong><\/p>\n

*by DartLab<\/td>\n<\/tr>\n

Treatment of multiple sclerosis with anti-CD154: a phase II double-blind partial cross-over clinical trial (IDEC\/ITN).<\/td>\nMechanistic<\/td>\nKasper<\/td>\nmonitoring*<\/td>\n<\/tr>\n
A trial of a CD40 activated dendritic cell vaccine in patients with resected colorectal cancer (NCI).<\/td>\nPhase II<\/td>\nBarth<\/td>\nvaccine\/monitoring*<\/td>\n<\/tr>\n
The effect of CNTO 1275 on the immune responses of peripheral blood cells from subjects with relapsing forms of multiple sclerosis (Centocor).<\/td>\nMechanistic<\/td>\nKasper<\/td>\nmonitoring*<\/td>\n<\/tr>\n
Dose-escalation study of EMD 273066 administered with low-dose cyclophosphamide to subjects with epithelial cell adhesion molecule (EpCAM) positive advanced cancers.<\/td>\nPhase I<\/td>\nErnstoff<\/td>\ncellular<\/td>\n<\/tr>\n
Dose dependent induction of T regulatory cells by glatiramer acetate: a parallel mechanistic study to GA9016 (TEVA Pharmaceuticals)<\/td>\nMechanistic<\/td>\nKasper<\/td>\nmonitoring*<\/td>\n<\/tr>\n
Longitudinal study of mild cognitive Iimpairment and early Alzheimer\u2019s disease.<\/td>\nMonitor<\/td>\nSaykin<\/td>\ncytokine*<\/td>\n<\/tr>\n
Autologous PBSC and immunotherapy for myeloma.<\/td>\nPhase III<\/td>\nMeehan<\/td>\ncellular\/cytokine<\/td>\n<\/tr>\n
Immune mobilization of autologous PBSC with IL-2 and GM-CSF<\/td>\nPhase III<\/td>\nMeehan<\/td>\ncytokine<\/td>\n<\/tr>\n
Immunologic evaluation of peripheral blood.<\/td>\nMonitor<\/td>\nErnstoff<\/td>\nmonitoring<\/td>\n<\/tr>\n
Autologous tumor\/DC vaccine + IL-2 & IFN\u03b1 in renal \u00a0cell cancer.<\/td>\nPhase II<\/td>\nErnstoff<\/td>\nvaccine\/cytokine<\/td>\n<\/tr>\n
Pre-clinical studies for development of a DC in GBM<\/td>\nPilot<\/td>\nFadul<\/td>\nvaccine<\/td>\n<\/tr>\n
IL-2 in lymphodepleted primed melanoma patients.<\/td>\nPhase II<\/td>\nErnstoff<\/td>\ncytokine<\/td>\n<\/tr>\n
Adjuvant intra-nodal autologous DC in GBM.<\/td>\nPhase II<\/td>\nFadul<\/td>\nvaccine<\/td>\n<\/tr>\n
Cryoablation as immunomodulator in breast cancer (Sanarus).<\/td>\nPilot<\/td>\nBarth<\/td>\nvaccine\/monitoring*<\/td>\n<\/tr>\n
VEGF blockade autologous DC, IL-2, and IFNa-2b in renal cell cancer.<\/td>\nPhase II<\/td>\nErnstoff<\/td>\nvaccine\/cytokine<\/td>\n<\/tr>\n
Cellular immunoRx, after autologous PBST for myeloma.<\/td>\nPhase II<\/td>\nMeehan<\/td>\ncellular<\/td>\n<\/tr>\n
Modulation of immune system by VEGF in GBM.<\/td>\nPilot<\/td>\nFadul<\/td>\nantibody<\/td>\n<\/tr>\n
Melanoma and renal tumor tissue bank extension.<\/td>\nMonitor<\/td>\nErnstoff<\/td>\nmonitoring<\/td>\n<\/tr>\n
Immune endpoints in blood & BM myeloma and healthy subjects.<\/td>\nMonitor<\/td>\nMeehan<\/td>\nmonitoring<\/td>\n<\/tr>\n
Immunological effects of GM-CSF\/vaccine in renal cell cancer and melanoma.<\/td>\nPilot<\/td>\nErnstoff<\/td>\nvaccine\/cytokine<\/td>\n<\/tr>\n
Leukapheresis for immunological endpoints.<\/td>\nMonitor<\/td>\nErnstoff<\/td>\nmonitoring<\/td>\n<\/tr>\n
GM-CSF in patients with prostate cancer.<\/td>\nPilot<\/td>\nErnstoff<\/td>\ncytokine<\/td>\n<\/tr>\n
Bevacizumab + IL-2 in renal cell cancer.<\/td>\nPhase II<\/td>\nErnstoff<\/td>\ncytokine\/antibody<\/td>\n<\/tr>\n
Melacine plus IFNa-2b vs. IFNa-2b in melanoma.<\/td>\nPhase III<\/td>\nErnstoff<\/td>\nvaccine\/cytokine<\/td>\n<\/tr>\n
Induction of T regulatory cells in relapsing-remitting multiple sclerosis following treatment with anti-CD52 (Campath 1-H; Genzyme)<\/td>\nMechanistic<\/td>\nKasper<\/td>\ncellular\/\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 cytokine\/monitoring*<\/td>\n<\/tr>\n
Induction of T regulatory cells and the effect on B cells by IFNb-1b (Bayer)<\/td>\nMechanistic<\/td>\nKasper<\/td>\nmonitoring*<\/td>\n<\/tr>\n
The relationship between thymic activity, regulatory T-cells and functional immune status in organ transplantation with alemtuzumab (Campath-1H) pretreatment and tacrolimus monotherapy.<\/td>\nPilot<\/td>\nZuckerman<\/td>\ncellular\/monitoring*<\/td>\n<\/tr>\n
The effect of psychosocial and behaviorally-based interventions on biological outcomes of patients with an advanced cancer diagnosis (NIH).<\/td>\nPilot<\/td>\nBakitas<\/td>\ncellular\/\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 cytokine\/monitoring*<\/td>\n<\/tr>\n
Evaluation of the effect of age and prior immunity on the response to live or inactivated seasonal influenza vaccines in children (NIH).<\/td>\nPilot<\/td>\nWright<\/td>\ncellular\/cytokine\/monitoring*<\/td>\n<\/tr>\n
An open-label, dose-escalation, phase I study of the safety, tolerability and immunogenicity of the prime-boost regimen of the investigational 2012\/13 seasonal influenza DNA vaccine followed by the 2012\/2013 seasonal influenza trivalent inactivated vaccine (TIV) compared to TIV prime-TIV boost in children and adolescents ages 6-17 Years (NIH).<\/td>\nPhase I<\/td>\nWright<\/td>\ncellular\/cytokine\/monitoring*<\/td>\n<\/tr>\n
Immune monitoring of the effects of an RXR nuclear receptor agonist on peripheral blood mononuclear cells from patients with Parkinson\u2019s disease (Io Therapeutics, Inc.).<\/td>\nPhase I<\/td>\nChannon<\/td>\ncellular\/cytokine\/monitoring*<\/td>\n<\/tr>\n
Pilot studies to determine the effects of an RXR nuclear receptor agonist on peripheral blood mononuclear cells from healthy individuals (Io Therapeutics, Inc.).<\/td>\nPilot<\/td>\nChannon<\/td>\ncellular\/cytokine<\/td>\n<\/tr>\n
Pilot study to evaluate the efficacy and safety of plasma exchange with human albumin in patients with amyotrophic lateral sclerosis (Grifols Biologicals Inc.).<\/td>\nPhase I<\/td>\nChannon<\/td>\ncellular\/cytokine\/monitoring*<\/td>\n<\/tr>\n
A Phase I Study of De-immunized DI-Leu16-IL2 Immunocytokine administered subcutaneously in Patients with B-cell Non-Hodgkin Lymphoma (Alopexx Pharmaceuticals LLC).<\/td>\nPhase I<\/td>\nChannon<\/td>\ncellular\/cytokine\/monitoring*<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

DartLab offers a range of services to facilitate Phase I and II clinical trials, including panel development, cell staining, cell sorting, flow cytometry, and data analysis. To arrange services for a clinical trial, please contact Dr. Smith to consult on research needs and experimental design.   Previous Clinical Trials Title [\u2026] <\/p>\n

<\/div>\n

Read More<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":452,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-496","page","type-page","status-publish","hentry","author-2"],"jetpack_shortlink":"https:\/\/wp.me\/P9HkEC-80","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/geiselmed.dartmouth.edu\/dartlab\/wp-json\/wp\/v2\/pages\/496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/geiselmed.dartmouth.edu\/dartlab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/geiselmed.dartmouth.edu\/dartlab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/dartlab\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/dartlab\/wp-json\/wp\/v2\/comments?post=496"}],"version-history":[{"count":9,"href":"https:\/\/geiselmed.dartmouth.edu\/dartlab\/wp-json\/wp\/v2\/pages\/496\/revisions"}],"predecessor-version":[{"id":1194,"href":"https:\/\/geiselmed.dartmouth.edu\/dartlab\/wp-json\/wp\/v2\/pages\/496\/revisions\/1194"}],"up":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/dartlab\/wp-json\/wp\/v2\/pages\/452"}],"wp:attachment":[{"href":"https:\/\/geiselmed.dartmouth.edu\/dartlab\/wp-json\/wp\/v2\/media?parent=496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}